BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
BriaCell报告称，在接受Briacell的Bria-IMT方案治疗的可评估的2期晚期乳腺癌患者中，初期疾病控制率为61％；在先前ADC治疗失败的可评估患者中，报告的控制率为50％
- Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study
-
Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
- Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor "no longer observed" following BriaCell treatment
- 在BriaCell的关键性3期研究中，在使用相同配方治疗的可评估的2期患者中观察到的疾病控制率为61％
-
接受3期制剂治疗但先前抗体药物偶联物（ADC）治疗失败的可评估患者的疾病控制率为50％
- 在BriaCell治疗后 “不再观察到” 转移性肝肿瘤的先前4种疗法，包括ADC疗法，该疗法的受试者均失败